Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Monitoring of patient response to the anaesthetic drugs is an attractive improvement for achieving a correct balance of sedation level, increasing the chance of success in the right procedure of anaesthesia. Nowadays, there are no commercial tools able to ...
Continuous monitoring of anaesthetics infusion is demanded by anaesthesiologists to help in defining personalized dose, hence reducing risks and side effects. We propose the first piece of technology tailored explicitly to close the loop between anaesthesi ...
The live demonstration presents the innovative concept of a portable pen-device able to sense anaesthetic compounds over time for improved anaesthesiology practice. A custom Printed Circuit Board (PCB) manage in the event-based quasi-digital domain the sam ...
The technologies for continuous measurement of the anaesthetic agents circulating in body fluids are not mature yet, though some preliminary prototypes exist already. We present a control algorithm that based on the real measurement of propofol plasma conc ...
After a failure of "One-Size-Fits-All" approach on traditional treatment of diseases, the age of multi-faceted personalized medicine came into being for tailoring therapy to get the best response in the highest safety margin. Personalized drug dosage is on ...
EPFL2018
Controversy exists regarding the site where anesthetics act in the brain to produce sedation and unconsciousness. Actions in the cerebral cortex and thalamus are likely, although the relative importance of each site is unclear. We used in computo modeling ...
An A10 aptamer (Apt)-functionalized, sub-100 nm doxorubicin–polylactide (Doxo-PLA) nanoconjugate (NC) with controlled release profile was developed as an intravenous therapeutic strategy to effectively target and cytoreduce canine hemangiosarcoma (cHSA), a ...